Alkermes escalates bidding war for Avadel Pharmaceuticals to $2.37 billion, intensifying competition for specialty CNS assets amid broader industry consolidation pressure.
FDA grants full approval and expanded indication for AbbVie/Genmab’s Epkinly in follicular lymphoma, enabling second-line therapy and potentially reshaping treatment paradigms.
Moderna announces complete onshoring of mRNA production to Massachusetts facility, joining industry-wide pivot to U.S. manufacturing amid mounting supply chain security concerns.
Congressional report identifies $48 billion in U.S.-China pharmaceutical deals, warning of growing dependency and signaling potential regulatory scrutiny for cross-border operations.
M&A LANDSCAPE:
Google Ventures predicts accelerating biopharma M&A through 2026 as major players face patent cliffs worth $180 billion in revenue, with 14 significant transactions completed this quarter.
Alkermes’ pursuit of Avadel focuses on narcolepsy franchise despite analyst skepticism about commercial potential, highlighting premium valuations for commercial-stage CNS assets.
REGULATORY DEVELOPMENTS:
AbbVie/Genmab’s Epkinly converts from accelerated to full approval in lymphoma, establishing the first bispecific antibody with broad label expansion in hematologic malignancies.
Vanda Pharmaceuticals reports positive data for GLP-1 adjunct therapy targeting nausea and vomiting, advancing to Phase 3 trials with potential to address key tolerability barriers for obesity medications.
MANUFACTURING & SUPPLY CHAIN:
Moderna’s manufacturing repatriation represents a $420 million investment in U.S. operations, mitigating geopolitical risks while aligning with federal policies incentivizing domestic production.
Bipartisan Congressional analysis reveals China’s increasing control over pharmaceutical supply chains, with particular concentration in API manufacturing, generic production, and clinical trial outsourcing.
FURTHER NOTABLE ANALYSIS:
Industry leaders signal cost structure recalibration for cell and gene therapies, with shift toward outcomes-based contracting models to address unsustainable pricing paradigms.
Incoming Recursion Pharmaceuticals CEO pivots messaging from AI capabilities to measurable clinical outcomes, reflecting broader market expectations for tangible results from computational platforms.
